Please enter mandatory and valid details

Scale Cervical Cancer
Screening | No Extra Staff

Meet CytoSiA:
The Digital Cytology Solution Built to Scale Cervical Cancer Screening

The Challenge: Scaling Cervical Cancer Screening

Manual cervical cytology workflows are struggling to keep pace with increasing screening volumes, workforce shortages, and growing pressure for consistent, timely results.

The World Health Organization has set an ambitious global target, the 90-70-90 goals by 2030, with the aim of eliminating cervical cancer as a public health problem (defined as ≤4 cases per 100,000 women) by achieving:

  • 90% HPV vaccination for girls by age 15
  • 70% screening of women with a high-performance test by ages 35 and again at 45
  • 90% treatment rates for pre-cancer and invasive disease

If labs aren’t digitally equipped to accurately triage, quantify, and standardize screening at scale, these 2030 targets, and the broader goal of reducing cervical cancer incidence globally, will remain out of reach.

Our Solution: CytoSiA

CytoSiA is a complete digital cytology solution purpose-built to scale cervical cancer screening.

It combines Brightfield slide scanning, AI-powered triage, and automated reporting into a seamless, scalable workflow that helps labs deliver faster, more consistent results, without costly infrastructure or locked platforms.

Whether it is a routine diagnostic lab, regional center, national screening program, or mobile diagnostic outreach clinic, CytoSiA makes cervical cytology screening more efficient, accessible, and actionable, even in low-resource settings with limited on-site expertise.

Whether it is a routine diagnostic lab, regional center, national screening program, or mobile diagnostic outreach clinic, CytoSiA makes cervical cytology screening more efficient, accessible, and actionable, even in low-resource settings with limited on-site expertise.

How CytoSiA Works

Scan. Index. Analyze.

A seamless digital workflow from slide to structured report.

  • Scan – Digitize slides using OptraSCAN’s OS-SiX, OS-Lite, or OS-Ultra Brightfield scanners. The software is optimized for OptraSCAN systems but can be customized for third-party scanners or digital images.
  • Index – AI algorithms triage normal and abnormal cases and identify atypical cells, reducing manual review workload and improving focus.
  • Analyze – Automatically generate reports with probability-ranked cell images and summary visualizations, delivered in minutes.

Slide To Report - In Minutes

Slide
Scan
Index
Analyze
Slide
Scanner
Computer
Report

Scanning Options:

  • Slide Capacity: 6 to 480
  • Focus Method: Z-stacking + AI Autofocus
  • Proprietary Composite Imaging to reduce image size

Indexing & AI-Triage:

  • IMAGEPath automatically indexes all scanned slides, generating thumbnails, metadata, and navigational maps
  • CytoSiA simultaneously runs AI to flag Bethesda-classified abnormalities in real time, organizing cases by status and ID for rapid access

Cell Classification Report:

  • AI analyzes individual cells (e.g.,HSIL, LSIL, ASCUS, ASC-H), ranking atypical cells by probability and providing assisted and trusted visual diagnosis.
  • It produces a structured, clinician-ready report, complete with thumbnails, classification stats, and flagged regions. Full EMR/LIS interface.

What Makes CytoSiA Different

  • AI triage that flags high-confidence normal cases, reducing manual review time and fatigue
  • Ranks atypical cells by probability, allowing pathologists to focus where it matters most
  • Works with OptraSCAN scanners or existing infrastructure (no vendor lock-in)
  • Supports cytology smears
  • Designed for labs of any size, from hospitals to mobile screening units
  • Telepathology-ready for mobile outreach and remote expert review in underserved areas
  • Trained on millions of cervical cancer datasets with high sensitivity and specificity
Cervical Image
Cervical Image

CytoSiA is mobile-ready and cloud-connected, enabling programs to extend cervical cancer screening into communities that need it most.

Where CytoSiA Delivers the Most Impact

  • National cervical cancer screening programs scaling to reach millions of women
  • Public health labs in low middle income countries, which need fast, cost-effective triage
  • Mid- to high-volume diagnostic cytology labs looking to improve throughput and consistency
  • Academic institutions, NGOs, and global health initiatives expanding access to underserved regions
  • Telepathology networks and mobile screening units enabling remote diagnosis and expert collaboration
Parallelogram

What You Can Do with CytoSiA

  • Triage faster with AI that flags normal slides and helps prioritize atypical cases
  • Review smarter with probability-ranked cell images and visual summaries
  • Generate structured reports automatically, reducing manual work and errors
  • Integrate seamlessly with OptraSCAN or third-party digital workflows
  • Deploy in any setting from national labs to mobile screening units
  • Scale securely and affordably, across regions, programs, or entire countries
  • Improve reproducibility and reduce fatigue, even in high-volume labs
Video Thumbnail
00:00 / 00:00
Thank you for your interest in OptraSCAN Digital Pathology solutions!

Please fill out the form below with information related to your area of interest.
You will be contacted by one of OptraSCAN representatives shortly.

Please complete all questions with an asterisk (*)

Please enter mandatory and valid details
Loading
Your message has been sent. Thank you!
References
  1. World Health Organization (WHO).
    Cervical Cancer Elimination Initiative.
  2. International Agency for Research on Cancer (IARC),
    GLOBOCAN 2022. Cervical Cancer Fact Sheet.
  3. Tissuepathology.com. OptraScan to expand into
    digital cytology. January 31, 2020.
  4. Arbyn M et al. The performance of human papillomavirus
    testing in screening for cervical cancer. Cochrane Database, 2012.
  5. World Health Organization (WHO).
    Cervical cancer. Updated November 2022.